AbCellera Biologics Inc.
NASDAQ:ABCLBiotechnology
-$0.02 today
- Market cap
- $3.42B
- Beta
- 1.20
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.47
Volume 2.48M
Average 6.37M
Income Statement
Follow revenue through to earnings.
Revenue
$75.13M
FY 2025 · Annual
+160.6% YoYOperating Income
-$217.10M
FY 2025 · Annual
Net Income
-$146.41M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 375.2M | 485.42M | 38.03M | 28.83M | 75.13M |
| Cost of Revenue | 45.52M | 66.44M | 0 | 0 | 28.82M |
| Gross Profit | 329.69M | 418.99M | 38.03M | 28.83M | 46.31M |
| Gross Margin | 87.9% | 86.3% | 100.0% | 100.0% | 61.6% |
| Research & Development | 62.06M | 107.88M | 175.66M | 167.26M | 186.83M |
| Selling, General & Admin | 48.76M | 66.76M | 75.18M | 85.49M | 76.58M |
| Operating Expenses | 125.27M | 202.48M | 275.23M | 343.6M | 263.41M |
| Depreciation & Amortization | 17.25M | 33.1M | 30.89M | 97M | 28.82M |
| EBITDA | 239.15M | 260.17M | (192.16M) | (204.15M) | (148.77M) |
| EBITDA Margin | 63.7% | 53.6% | -505.3% | -708.0% | -198.0% |
| Operating Income | 204.41M | 216.51M | (237.21M) | (314.77M) | (217.1M) |
| Operating Margin | 54.5% | 44.6% | -623.8% | -1091.7% | -289.0% |
| Interest Income | 3.33M | 16.08M | 42.25M | 38.47M | 28.33M |
| Interest Expense | 5.23M | 4.05M | 0 | 0 | 0 |
| Other Income / Expenses | 14.74M | 22.59M | 63.18M | 114.37M | 39.51M |
| Income Before Tax | 219.15M | 239.1M | (174.03M) | (200.4M) | (177.6M) |
| Pre-Tax Margin | 58.4% | 49.3% | -457.7% | -695.0% | -236.4% |
| Income Tax Expense | 65.69M | 80.58M | (27.63M) | (37.54M) | (31.18M) |
| Net Income | 153.46M | 158.52M | (146.4M) | (162.86M) | (146.41M) |
| Net Margin | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% |
| EPS (Basic) | 0.56 | 0.56 | (0.51) | (0.55) | (0.49) |
| EPS (Diluted) | 0.48 | 0.50 | (0.51) | (0.55) | (0.49) |
| 275.76M | 285.06M | 289.17M | 294.33M | 298.71M | |
| 318.29M | 314.83M | 289.17M | 294.33M | 298.71M |
ABCL Earnings Waterfall · TTM
NASDAQ:ABCL · Revenue to Net Income
Key Ratios
Analysis
$67.9M of revenue converted into -$148.3M of net income for the selected period. Gross margin is -80.7% and net margin is -572.7%, showing how much revenue survives after costs and taxes. EPS is $-0.48, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 8-K | Current report | Nov 9, 2026 |
How much revenue does ABCL generate?
AbCellera Biologics Inc. (ABCL) reported $75.13M of revenue in fiscal 2025.
Is ABCL profitable?
AbCellera Biologics Inc. (ABCL) reported -$146.41M of net income, with a net margin of -194.9%.
Continue the stock analysis
Jump to another research area for this company.